Efsubaglutide Alfa
Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents
Shanghai Yinnuo Pharmaceutical Technology Co · Phase 1 · Recruiting · Enrollment 36
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Efsubaglutide Alfa 5 mg QW | n/r | n/r | n/r | n/r |
| Efsubaglutide Alfa 10 mg QW | n/r | n/r | n/r | n/r |
| Efsubaglutide Alfa 20 mg QW | n/r | n/r | n/r | n/r |
| Efsubaglutide Alfa placebo | n/r | n/r | n/r | n/r |
Not shown
- Efsubaglutide Alfa 5 mg QW: endpoint not reported
- Efsubaglutide Alfa 10 mg QW: endpoint not reported
- Efsubaglutide Alfa 20 mg QW: endpoint not reported
- Efsubaglutide Alfa placebo: endpoint not reported